Hypersensitivity reactions to neuromuscular blocking agents

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2809-2825

  Mertes, P M ^a,b   Aimone Gastin, I ^b,c   Gueant Rodriguez R M ^b,c   Mouton Faivre, C ^a   Audibert, G ^a,b   O'Brien, J ^a   Frendt, D ^a   Brezeanu, M ^a   Bouaziz, H ^a   Guéant, Jean Louis ^b,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c CHU NANCY BRABOIS   (France)

Author keywords

Allergy; Anaesthesia; Anaphylaxis; Flow cytometry; IgE; Neuromuscular blocking agents; Skin test

Indexed keywords

ADRENALIN; AMMONIA; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR; CISATRACURIUM; CORTICOSTEROID; DRUG ANTIBODY; IMMUNOGLOBULIN E; MUSCARINIC RECEPTOR; MUSCLE RELAXANT AGENT; NEUROMUSCULAR BLOCKING AGENT; NICOTINIC RECEPTOR; PANCURONIUM; RAPACURONIUM BROMIDE; ROCURONIUM; SUXAMETHONIUM; TRYPTASE;

ANAPHYLAXIS; ANESTHESIA; ANTIBODY PRODUCTION; ANTIGEN BINDING; BASOPHIL DEGRANULATION; BASOPHIL DEGRANULATION TEST; BINDING AFFINITY; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYMPTOM; CLINICAL FEATURE; COST BENEFIT ANALYSIS; CROSS REACTION; DELAYED HYPERSENSITIVITY; DEPOLARIZATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG SENSITIZATION; DRUG STRUCTURE; EDEMA; ERYTHEMA; FAMILY HISTORY; FLOW CYTOMETRY; HEART ARREST; HIGH RISK PATIENT; HISTAMINE RELEASE; HUMAN; HYPERKALEMIA; HYPOTENSION; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INTRACUTANEOUS TEST; MALIGNANT HYPERTHERMIA; MAST CELL DEGRANULATION; MUSCLE SPASM; MYOTONIA; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SHOCK; SKIN TEST; TACHYCARDIA; URTICARIA;

ANAPHYLAXIS; ANIMALS; DRUG HYPERSENSITIVITY; HUMANS; NEUROMUSCULAR BLOCKING AGENTS; RISK FACTORS; SKIN TESTS;

EID: 61849139323     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369704     Document Type: Review

References (178)

1. Wishart DS, Knox C, Guo AC, et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901-6.
2. Wishart DS, Knox C, Guo AC, et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34: D668-72.
3. Ishizawa Y. Mechanisms of anesthetic actions and the brain. J Anesth 2007; 21: 187-99.
4. Paton WD. Histamine release by compounds of simple chemical structure. Pharmacol Rev 1957; 9: 269-328.
5. Watkins J, Clarke RS. Report of a symposium: Adverse responses to intravenous agents. Br J Anaesth 1978; 50: 1159-64.
6. Jerums G, Whittingham S, Wilson P. Anaphylaxis to suxamethonium. A case report. Br J Anaesth 1967; 39: 73-7.
7. Fisher MM. Intradermal testing after severe histamine reactions to intravenous drugs used in anaesthesia. Anaesth Intensive Care 1976; 4: 97-104.
8. Sigiel M, Laxenaire MC, Moneret-Vautrin DA, Condi M, Jacob F, Picard JP. Trois cas de choc anaphylactique à la Célocurine. Anesth Analg 1975; 32: 447-62.
9. Vervloet D, Arnaud A, Vellieux P, Kaplanski S, Charpin J. Anaphylactic type of accidents due to myorelaxing agents during general anesthesia. Clinical and biological study. Nouv Presse Med 1977; 6: 725-8.
10. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
11. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24.
12. Scala E, Guerra EC, Giani M, et al. Delayed allergic reaction to suxamethonium driven by oligoclonal Th1-skewed CD4+CCR4+ IFN-gamma+ memory T cells. Int Arch Allergy Immunol 2006; 141: 24-30.
13. Delgado J, Quiralte J, Castillo R, Blanco C, Molero R, Carrillo T. Systemic contact dermatitis from suxamethonium. Contact Dermatitis 1996; 35: 120-1.
14. Mertes PM, Alla F, Laxenaire MC. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99: 536-45.
15. Light KP, Lovell AT, Butt H, Fauvel NJ, Holdcroft A. Adverse effects of neuromuscular blocking agents based on yellow card reporting in the UK: are there differences between males and females? Pharmacoepidemiol Drug Saf 2006; 15: 151-60.
16. Laake JH, Rottingen JA. Rocuronium and anaphylaxis - a statistical challenge. Acta Anaesthesiol Scand 2001; 45: 1196-203.
17. Sachs RM, Bortnichak EA. An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986; 81: 49-55.
18. Tsong Y. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. J Biopharm Stat 1995; 5: 95-114.
19. Mertes PM, Guttormsen AB, Harboe T, et al. Can spontaneous adverse event reporting systems really be used to compare rates of adverse events between drugs? Anesth Analg 2007; 104: 471-2.
20. Fisher MM, More DG. The epidemiology and clinical features of anaphylactic reactions in anaesthesia. Anaesth Intensive Care 1981; 9: 226-34.
21. Laxenaire MC. What is the real risk of drug hypersensitivity in anesthesia? Incidence. Clinical aspects. Morbidity-mortality. Substances responsible. Ann Fr Anesth Reanim 2002; 21(Suppl 1): 38s-54s.
22. Mertes PM, Laxenaire MC. Allergic reactions occurring during anaesthesia. Eur J Anaesthesiol 2002; 19: 240-62.
23. Charuluxananan S, Punjasawadwong Y, Suraseranivongse S, et al. The Thai Anesthesia Incidents Study (THAI Study) of anesthetic outcomes: II. Anesthetic profiles and adverse events. J Med Assoc Thai 2005; 88(Suppl 7): S14-29.
24. Whittington T, Fisher MM. Anaphylactic and anaphylactoid reactions. Clinical Anaesthesiology. B Clin Anaesthesiol 1998; 12: 301-23.
25. Laxenaire MC. Epidémiologie des réactions anaphylactoïdes peranesthésiques. Quatrième enquête multicentrique (juillet 1994-décembre 1996). Ann Fr Anesth Reanim 1999; 18: 796-809.
26. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: A 6-year single-center follow-up study. Anesthesiology 2005; 102: 897-903.
27. Galletly DC, Treuren BC. Anaphylactoid reactions during anaesthesia. Seven years' experience of intradermal testing. Anaesthesia 1985; 40: 329-33.
28. Fisher M, Baldo BA. Anaphylaxis during anaesthesia: Current aspects of diagnosis and prevention. Eur J Anaesthesiol 1994; 11: 263-84.
29. Mertes PM, Laxenaire MC. Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002). Ann Fr Anesth Reanim 2004; 23: 1133-43.
30. Florvaag E, Johansson SG, Oman H, et al. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand 2005; 49: 437-44.
31. Garvey LH, Roed-Petersen J, Menne T, Husum B. Danish Anaesthesia Allergy Centre - preliminary results. Acta Anaesthesiol Scand 2001; 45: 1204-9.
32. Kroigaard M, Garvey LH, Menne T, Husum B. Allergic reactions in anaesthesia: Are suspected causes confirmed on subsequent testing? Br J Anaesth 2005; 95: 468-71.
33. Bhananker SM, O'Donnell JT, Salemi JR, Bishop MJ. The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: An analysis of food and drug administration reporting of adverse events. Anesth Analg 2005; 101: 819-22.
34. Currie M, Webb RK, Williamson JA, Russell WJ, Mackay P. The Australian incident monitoring study. Clinical anaphylaxis: An analysis of 2000 incident reports. Anaesth Intensive Care 1993; 21: 621-5.
35. Mitsuhata H, Matsumoto S, Hasegawa J. The epidemiology and clinical features of anaphylactic and anaphylactoid reactions in the perioperative period in Japan. Masui 1992; 41: 1664-9.
36. Axon AD, Hunter JM. Editorial III: Anaphylaxis and anaesthesia - all clear now? Br J Anaesth 2004; 93: 501-4.
37. Lienhart A, Auroy Y, Pequignot F, et al. Survey of anesthesia-related mortality in France. Anesthesiology 2006; 105: 1087-97.
38. Laxenaire M, Mertes PM, GERAP. Anaphylaxis during anaesthesia. Results of a 2 year survey in France. Br J Anaesth 2001; 21: 549-58.
39. Fisher MM, Doig GS. Prevention of anaphylactic reactions to anaesthetic drugs. Drug Saf 2004; 27: 393-410.
40. Guttormsen AB. Allergic reactions during anaesthesia - increased attention to the problem in Denmark and Norway. Acta Anaesthesiol Scand 2001; 45: 1189-90.
41. Heier T, Guttormsen AB. Anaphylactic reactions during induction of anaesthesia using rocuronium for muscle relaxation: A report including 3 cases. Acta Anaesthesiol Scand 2000; 44: 775-81.
42. Laxenaire MC, Gastin I, Moneret-Vautrin DA, Widmer S, Gueant JL. Cross-reactivity of rocuronium with other neuromuscular blocking agents. Eur J Anaesthesiol Suppl 1995; 11: 55-64.
43. Rose M, Fisher M. Rocuronium: High risk for anaphylaxis? Br J Anaesth 2001; 86: 678-82.
44. Watkins J. Incidence of UK reactions involving rocuronium may simply reflect market use. Br J Anaesth 2001; 87: 522.
45. Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg 2003; 97: 1381-95.
46. Porri F, Lemiere C, Birnbaum J, et al. Prevalence of muscle relaxant sensitivity in a general population: Implications for a preoperative screening. Clin Exp Allergy 1999; 29: 72-5.
47. Moneret-Vautrin DA, Renaudin JM, Kanny G, Widler S, Hanesse B, Dezfoulian B. Prospective study of the latent sensitization to muscle relaxants. In: Dehling AK, Huerat-Lopez JG, Eds. Progress in allergy and clinical immunology. Cancun: Hogrefe and Huber 1997; 361-76.
48. Bermejo N, Guéant J, Mata E, Gerard P, Moneret-Vautrin D, Laxenaire M. Platelet serotonin is a mediator potentially involved in anaphylactic reaction to neuromuscular blocking drugs. Br J Anaesth 1993; 70: 322-5.
49. Pichler WJ. T cells in drug allergy. Curr Allergy Asthma Rep 2002; 2: 9-15.
50. Aubert N, Mertes PM, Janaszak M, et al. Dendritic cells present neuromuscular blocking agent-related epitopes to T cells from allergic patients. Allergy 2004; 59: 1022-3.
51. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983; 306: 262-4.
52. Baldo BA, Harle DG. Drug allergenic determinants. In: Baldo BA, Ed. Molecular approaches to the study of allergens Monographs in allergy. Basel: Karger 1990; 11-51.
53. de Weck AL. Immunochemical particularities of anaphylactic reactions to compounds used in anesthesia. Ann Fr Anesth Reanim 1993; 12: 126-30
54. Moneret-Vautrin DA, Gueant JL, Kamel L, Laxenaire MC, el Kholty S, Nicolas JP. Anaphylaxis to muscle relaxants: Crosssensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases. J Allergy Clin Immunol 1988; 82: 745-52.
55. Leynadier F, Dry J. Anaphylaxis to muscle-relaxant drugs: Study of cross-reactivity by skin tests. Int Arch Allergy Appl Immunol 1991; 94: 349-53.
56. Fisher MM. Anaphylaxis to muscle relaxants: Cross sensitivity between relaxants. Anaesth Intensive Care 1980; 8: 211-3.
57. Fisher MM. Cisatracurium and atracurium as antigens. Anaesth Intensive Care 1999; 27: 369-70.
58. Fisher MM, Baldo BA. Immunoassays in the diagnosis of anaphylaxis to neuromuscular blocking drugs: The value of morphine for the detection of IgE antibodies in allergic subjects. Anaesth Intensive Care 2000; 28: 167-70.
59. Gueant JL, Mata E, Masson C, et al. Non-specific cross-reactivity of hydrophobic serum IgE to hydrophobic drugs. Mol Immunol 1995; 32: 259-66.
60. Gueant JL, Mata E, Namour F, et al. Criteria of evaluation and of interpretation of Sepharose drug IgE-RIA to anaesthetic drugs. Allergy 1999; 54(Suppl 58): 17-22.
61. Fisher M. Anaphylaxis to anaesthetic drugs. Novartis Found Symp 2004; 257: 193-202; discussion -10, 76-85.
62. Moneret-Vautrin DA, Laxenaire MC. The risk of allergy related to general anaesthesia. Clin Exp Allergy 1993; 23: 629-33.
63. Didier A, Cador D, Bongrand P, et al. Role of the quaternary ammonium ion determinants in allergy to muscle relaxants. J Allergy Clin Immunol 1987; 79: 578-84.
64. Birnbaum J, Vervloet D. Allergy to muscle relaxants. Clin Rev Allergy 1991; 9: 281-93.
65. Gueant JL, Masson C, Laxenaire MC. Biological tests for diagnosing the IgE-mediate allergy to anaesthetic drugs. In: Assem K, Ed. Monographs in Allergy. Basel: Karger 1992; 94-107.
66. Romano A, Gueant-Rodriguez RM, Viola M, Gaeta F, Caruso C, Gueant JL. Cross-reactivity among drugs: Clinical problems. Toxicology 2005; 209: 169-79.
67. Mertes PM, Laxenaire MC. Adverse reactions to neuromuscular blocking agents. Curr Allergy Asthma Rep 2004; 4: 7-16.
68. Pepys J, Pepys EO, Baldo BA, Whitwam JG. Anaphylactic/anaphylactoid reactions to anaesthetic and associated agents. Skin prick tests in aetiological diagnosis. Anaesthesia 1994; 49: 470-5.
69. Florvaag E, Johansson SG, Oman H, Harboe T, Nopp A. Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 2006; 61: 49-55.
70. Harboe T, Johansson SG, Florvaag E, Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007; 62: 1445-50.
71. Ebo DG, Venemalm L, Bridts CH, et al. Immunoglobulin E antibodies to rocuronium: A new diagnostic tool. Anesthesiology 2007; 107: 253-9
72. Nielsen GD, Larsen ST, Olsen O, et al. Do indoor chemicals promote development of airway allergy? Indoor Air 2007; 17: 236-55.
73. Vincent G, Kopferschmitt-Kubler MC, Mirabel P, Pauli G, Millet M. Sampling and analysis of quaternary ammonium compounds (QACs) traces in indoor atmosphere. Environ Monit Assess 2007; 133: 25-30.
74. Fujita T. Delayed hypersensitivity reaction to succinylcholine. Tohoku J Exp Med 1970; 102: 33-5.
75. Seebert CT. Delayed anaphylaxis in an anesthetized patient. South Med J 1971; 64: 804-6.
76. Luque I, Leyva L, Jose Torres M, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56: 611-8.
77. von Greyerz S, Burkhart C, Pichler WJ. Molecular basis of drug recognition by specific T-cell receptors. Int Arch Allergy Immunol 1999; 119: 173-80.
78. Moss J. Muscle relaxants and histamine release. Acta Anaesthesiol Scand Suppl 1995; 106: 7-12.
79. Doenicke A, Moss J, Lorenz W, Hoernecke R, Gottardis M. Are hypotension and rash after atracurium really caused by histamine release? Anesth Analg 1994; 78: 967-72.
80. Cannon JE, Fahey MR, Moss J, Miller RD. Large doses of vecuronium and plasma histamine concentrations. Can J Anaesth 1988; 35: 350-3.
81. Doenicke A, Moss J, Toledano A, Hoernecke R, Lorenz W, Ostwald P. Administration of H1 and H2 antagonists for chemoprophylaxis: A double-blind, placebo-controlled study in healthy volunteers. J Clin Pharmacol 1997; 37: 140-6.
82. Doenicke AW, Czeslick E, Moss J, Hoernecke R. Onset time, endotracheal intubating conditions, and plasma histamine after cisatracurium and vecuronium administration. Anesth Analg 1998; 87: 434-8.
83. Koppert W, Blunk JA, Petersen LJ, Skov P, Rentsch K, Schmelz M. Different patterns of mast cell activation by muscle relaxants in human skin. Anesthesiology 2001; 95: 659-67.
84. McManus MC. Neuromuscular blockers in surgery and intensive care, Part 1. Am J Health Syst Pharm 2001; 58: 2287-99.
85. Hunter JM. New neuromuscular blocking drugs. N Engl J Med 1995; 332: 1691-9.
86. Rajchert DM, Pasquariello CA, Watcha MF, Schreiner MS. Rapacuronium and the risk of bronchospasm in pediatric patients. Anesth Analg 2002; 94: 488-93.
87. Fine GF, Motoyama EK, Brandom BW, Fertal KM, Mutich R, Davis PJ. The effect on lung mechanics in anesthetized children with rapacuronium: A comparative study with mivacurium. Anesth Analg 2002; 95: 56-61.
88. Tobias JD, Johnson JO, Sprague K, Johnson G. Effects of rapacuronium on respiratory function during general anesthesia: A comparison with cis-atracurium. Anesthesiology 2001; 95: 908-12.
89. Jooste E, Zhang Y, Emala CW. Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle. Anesthesiology 2005; 102: 117-24.
90. Jooste EH, Sharma A, Zhang Y, Emala CW. Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. Anesthesiology 2005; 103: 1195-203.
91. Jooste E, Klafter F, Hirshman CA, Emala CW. A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism. Anesthesiology 2003; 98: 906-11.
92. Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand 2008; 52: 175-81.
93. Stellato C, de Paulis A, Cirillo R, Mastronardi P, Mazzarella B, Marone G. Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 1991; 74: 1078-86.
94. Jacobsen J, Secher NH. Slowing of the heart during anaphylactic shock. A report of five cases. Acta Anaesthesiol Scand 1988; 32: 401-3.
95. Laxenaire MC. Drugs and other agents involved in anaphylactic shock occurring during anaesthesia. A French multicenter epidemiological inquiry. Ann Fr Anesth Reanim 1993; 12: 91-6.
96. Mertes PM, Laxenaire MC, Lienhart A, et al. Reducing the risk of anaphylaxis during anaesthesia: Guidelines for clinical practice. J Investig Allergol Clin Immunol 2005; 15: 91-101.
97. Mertes PM, Laxenaire M. Anaphylaxis during general anaesthesia. Prevention and management. CNS Drugs 2000; 14: 115-33.
98. Dewachter P, Raeth-Fries I, Jouan-Hureaux V, et al. A comparison of epinephrine only, arginine vasopressin only, and epinephrine followed by arginine vasopressin on the survival rate in a rat model of anaphylactic shock. Anesthesiology 2007; 106: 977-83.
99. Rocq N, Favier JC, Plancade D, Steiner T, Mertes PM. Successful use of terlipressin in post-cardiac arrest resuscitation after an epinephrine-resistant anaphylactic shock to suxamethonium. Anesthesiology 2007; 107: 166-7.
100. Chacko T, Ledford D. Peri-anesthetic anaphylaxis. Immunol Allergy Clin North Am 2007; 27: 213-30.
101. Ben Abraham R, Cahana A, Krivosic-Horber RM, Perel A. Malignant hyperthermia susceptibility: Anaesthetic implications and risk stratification. QJM 1997; 90: 13-8.
102. Naguib M, Magboul MM. Adverse effects of neuromuscular blockers and their antagonists. Drug Saf 1998; 18: 99-116.
103. Iaizzo PA, Lehmann-Horn F. Anesthetic complications in muscle disorders. Anesthesiology 1995; 82: 1093-6.
104. Kampe S, Krombach JW, Diefenbach C. Muscle relaxants. Best Pract Res Clin Anaesthesiol 2003; 17: 137-46.
105. Book WJ, Abel M, Eisenkraft JB. Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management. Drug Saf 1994; 10: 331-49.
106. Karila C, Brunet-Langot D, Labbez F, et al. Anaphylaxis during anesthesia: Results of a 12-year survey at a French pediatric center. Allergy 2005; 60: 828-34.
107. Duvaldestin P, Wigdorowicz C, Gabriel I. Anaphylactic shock to neuromuscular blocking agent: A familial history. Anesthesiology 1999; 90: 1211-2.
108. Fisher MM. The preoperative detection of risk of anaphylaxis during anaesthesia. Anaesth Intensive Care 2007; 35: 899-902.
109. Laxenaire MC, Moneret-Vautrin DA, Vervloet D. The French experience of anaphylactoid reactions. Int Anesthesiol Clin 1985; 23: 145-60.
110. Laforest M, More D, Fisher M. Predisposing factors in anaphylactoid reactions to anaesthetic drugs in an Australian population: The role of allergy, atopy and previous anaesthesia. Anaesth Intensive Care 1980; 8: 454-9.
111. Fee JP, McDonald JR, Clarke RS, Dundee JW, Pal PK. The incidence of atopy and allergy in 10 000 preanaesthetic patients [proceedings]. Br J Anaesth 1978; 50: 74.
112. Fisher MM, Outhred A, Bowey CJ. Can clinical anaphylaxis to anaesthetic drugs be predicted from allergic history? Br J Anaesth 1987; 59: 690-2.
113. Charpin D, Benzarti M, Hemon Y, et al. Atopy and anaphylactic reactions to suxamethonium. J Allergy Clin Immunol 1988; 82: 356-60
114. Kroigaard M, Garvey LH, Gillberg L, et al. Scandinavian clinical practice guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia. Acta Anaesthesiol Scand 2007; 51: 655-70.
115. Ebo DG, Fisher MM, Hagendorens MM, Bridts CH, Stevens WJ. Anaphylaxis during anaesthesia: Diagnostic approach. Allergy 2007; 62: 471-87.
116. Mertes PM, Moneret-Vautrin DA, Leynadier F, Laxenaire MC. Skin reactions to intradermal neuromuscular blocking agent injections: A randomized multicenter trial in healthy volunteers. Anesthesiology 2007; 107: 245-52.
117. Ebo DG, Bridts CH, Hagendorens MM, Aerts NE, De Clerck LS, Stevens WJ. Basophil activation test by flow cytometry: Present and future applications in allergology. Cytometry B Clin Cytom 2008; 74B: 201-10.
118. Laroche D, Lefrancois C, Gerard JL, et al. Early diagnosis of anaphylactic reactions to neuromuscular blocking drugs. Br J Anaesth 1992; 69: 611-4.
119. Guttormsen AB, Johansson SG, Oman H, Wilhelmsen V, Nopp A. No consumption of IgE antibody in serum during allergic drug anaphylaxis. Allergy 2007; 62: 1326-30.
120. Mertes PM, Laxenaire MC. Allergy and anaphylaxis in anaesthesia. Minerva Anestesiol 2004; 70: 285-91.
121. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-6.
122. Laroche D, Dubois F, Gérard J, Lefrançois C, André B, Vergnaud M. Radioimmunoassy for plasma histamine: A study of false positive and false negative values. Br J Anaesth 1995; 74: 430-7.
123. Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology 1991; 75: 945-9.
124. Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 1998; 80: 26-9.
125. Ebo DG, Hagendorens MM, Bridts CH, Stevens WJ. Immediate-type allergy to drugs and related compounds: Evaluation and management. Acta Clin Belg 2005; 60: 350-61.
126. Hogan AD, Schwartz LB. Markers of mast cell degranulation. Methods 1997; 13: 43-52.
127. Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987; 138: 2184-9.
128. Baldo BA, Fisher MM. Anaphylaxis to muscle relaxant drugs: cross-reactivity and molecular basis of binding of IgE antibodies detected by radioimmunoassay. Mol Immunol 1983; 20: 1393-400.
129. Harle DG, Baldo BA, Fisher MM. Cross-reactivity of metocurine, atracurium, vecuronium and fazadinium with IgE antibodies from patients unexposed to these drugs but allergic to other myoneural blocking drugs. Br J Anaesth 1985; 57: 1073-6.
130. Baldo BA, Fisher MM. Diagnosis of IgE-dependent anaphylaxis to neuromuscular blocking drugs, thiopentone and opioids. Ann Fr Anesth Reanim 1993; 12: 173-81.
131. Gueant JL, Mata E, Monin B, et al. Evaluation of a new reactive solid phase for radioimmunoassay of serum specific IgE against muscle relaxant drugs. Allergy 1991; 46: 452-8.
132. Gueant JL, Aimone-Gastin I, Namour F, Laroche D, Bellou A, Laxenaire MC. Diagnosis and pathogenesis of the anaphylactic and anaphylactoid reactions to anaesthetics. Clin Exp Allergy 1998; 28 (Suppl 4): 65-70.
133. Guilloux L, Ricard-Blum S, Ville G, Motin J. A new radioimmunoassay using a commercially available solid support for the detection of IgE antibodies against muscle relaxants. J Allergy Clin Immunol 1992; 90: 153-9.
134. Soetens FM. Anaphylaxis during anaesthesia: Diagnosis and treatment. Acta Anaesthesiol Belg 2004; 55: 229-37.
135. Moneret-Vautrin DA, Kanny G. Anaphylaxis to muscle relaxants: Rational for skin tests. Allerg Immunol (Paris) 2002; 34: 233-40.
136. Moneret-Vautrin DA. Skin tests for diagnosis of curare allergy. Ann Fr Anesth Reanim 2002; 21(Suppl 1): 97s-107s.
137. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
138. Fisher MM, Merefield D, Baldo B. Failure to prevent an anaphylactic reaction to a second neuromuscular blocking drug during anaesthesia. Br J Anaesth 1999; 82: 770-3.
139. Leynadier F, Sansarricq M, Didier JM, Dry J. Prick tests in the diagnosis of anaphylaxis to general anaesthetics. Br J Anaesth 1987; 59: 683-9.
140. Fisher MM, Bowey CJ. Intradermal compared with prick testing in the diagnosis of anaesthetic allergy. Br J Anaesth 1997; 79: 59-63.
141. Levy JH, Gottge M, Szlam F, Zaffer R, McCall C. Weal and flare responses to intradermal rocuronium and cisatracurium in humans. Br J Anaesth 2000; 85: 844-9.
142. Berg CM, Heier T, Wilhelmsen V, Florvaag E. Rocuronium and cisatracurium-positive skin tests in non-allergic volunteers: determination of drug concentration thresholds using a dilution titration technique. Acta Anaesthesiol Scand 2003; 47: 576-82.
143. Dhonneur G, Combes X, Chassard D, Merle JC. Skin sensitivity to rocuronium and vecuronium: A randomized controlled prick-testing study in healthy volunteers. Anesth Analg 2004; 98: 986-9.
144. Mertes PM, Laxenaire MC, Malinovsky JM, Florvaag E, Moneret-Vautrin DA. Skin sensitivity to rocuronium and vecuronium: Prick-tests are not intradermal test. Anesth Analg 2005; 100: 1539.
145. Fisher M. Prick testing for neuromuscular blocking drugs. Anesth Analg 2004; 99: 1880.
146. Thacker MA, Davis FM. Subsequent general anaesthesia in patients with a history of previous anaphylactoid/anaphylactic reaction to muscle relaxant. Anaesth Intensive Care 1999; 27: 190-3.
147. Laxenaire MC, Moneret-Vautrin DA. Allergy and anaesthesia. Curr Opin Anaesthesiol 1992; 5: 436-41.
148. McKinnon RP, Wildsmith JA. Histaminoid reactions in anaesthesia. Br J Anaesth 1995; 74: 217-28.
149. Mata E, Gueant JL, Moneret-Vautrin DA, et al. Clinical evaluation of in vitro leukocyte histamine release in allergy to muscle relaxant drugs. Allergy 1992; 47: 471-6.
150. Assem E. Release of eosinophil cationic protein (ECP) in anaphylactoid anaesthetic reactions in vivo and in vitro. Agents Actions 1994; 41: C11-C3.
151. Assem E. Leukotriene C4 release from blood cells in vitro in patients with anaphylactoid reactions to neuromuscular blockers. Agents Actions 1993; 38: C242-C4.
152. Abuaf N, Rajoely B, Ghazouani E, et al. Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol 1999; 104: 411-8.
153. Sabbah A, Drouet M, Sainte-Laudry J, Lauret MG, Loiry M. Contribution of flow cytometry to allergologic diagnosis. Allerg Immunol (Paris) 1997; 29: 15-21.
154. Sainte-Laudy J, Vallon C, Guerin JC. Analysis of membrane expression of the CD63 human basophil activation marker. Applications to allergologic diagnosis. Allerg Immunol (Paris) 1994; 26: 211-4.
155. Monneret G, Benoit Y, Gutowski M, Bienvenu J. Detection of basophil activation by flow cytométrie in patients with allergy to muscle-relaxant drugs. Anesthesiology 2000; 92: 275-7.
156. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow cytometry: Recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy 2005; 3: 9.
157. de Weck AL, Sanz ML, Gamboa PM, et al. Diagnostic tests based on human basophils: More potentials and perspectives than pitfalls. Int Arch Allergy Immunol 2008; 146: 177-89.
158. Boumiza R, Monneret G, Forissier MF, et al. Marked improvement of the basophil activation test by detecting CD203c instead of CD63. Clin Exp Allergy 2003; 33: 259-65.
159. Sudheer PS, Hall JE, Read GF, Rowbottom AW, Williams PE. Flow cytometric investigation of peri-anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia 2005; 60: 251-6.
160. Ebo DG, Sainte-Laudy J, Bridts CH, et al. Flow-assisted allergy diagnosis: Current applications and future perspectives. Allergy 2006; 61: 1028-39.
161. Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bienvenu J. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol 2002; 102: 192-9.
162. Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006; 61: 311-5.
163. Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006; 61: 935-9.
164. Dexter F, Gan TJ, Naguib M, Lubarsky DA. Cost identification analysis for succinylcholine. Anesth Analg 2001; 92: 693-9.
165. Allen TK, Habib AS, Dear GL, White W, Lubarsky DA, Gan TJ. How much are patients willing to pay to avoid postoperative muscle pain associated with succinylcholine? J Clin Anesth 2007; 19: 601-8.
166. Ortega A, Sarobe C, Iribarren MJ, Giraldez J. Cost analysis of neuromuscular blocking agents in the operating room: Cisatracurium, atracurium, vecuronium and rocuronium. Pharm World Sci 2000; 22: 82-7
167. Moss J, Roizen MF, Nordby EJ, et al. Decreased incidence and mortality of anaphylaxis to chymopapain. Anesth Analg 1985; 64: 1197-201.
168. Lorenz W, Duda D, Dick W, et al. Incidence and clinical importance of perioperative histamine release: Randomised study of volume loading and antihistamines after induction of anaesthesia. Trial Group Mainz/ Marburg. Lancet 1994; 343: 933-40.
169. Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Antihistamine prophylaxis permits rapid vancomycin infusion. Crit Care Med 1999; 27: 1732-7.
170. Hosking MP, Lennon RL, Gronert GA. Combined H1 and H2 receptor blockade attenuates the cardiovascular effects of high-dose atracurium for rapid sequence endotracheal intubation. Anesth Analg 1988; 67: 1089-92.
171. McKinnon RP. Allergic reactions during anaesthesia. Curr Opin Anaesth 1996; 9: 267-70.
172. Vervloet D, Arnaud A, Senft M, et al. Anaphylactic reactions to suxamethonium: Prevention of mediator release by choline. J Allergy Clin Immunol 1985: 222-5.
173. Thomas H, Eledjam JJ, Macheboeuf M, d'Athis F, Mares P, Bousquet J. Rapid pre-operative immunotherapy in a patient allergic to muscle relaxants. Eur J Anaesthesiol 1988; 5: 385-9.
174. Moneret-Vautrin DA, Kanny G, Gueant JL, Widmer S, Laxenaire MC. Prevention by monovalent haptens of IgE-dependent leucocyte histamine release to muscle relaxants. Int Arch Allergy Immunol 1995; 107: 172-5.
175. Philbin DM, Moss J, Akins CW, et al. The use of H1 and H2 histamine antagonists with morphine anesthesia: A double-blind study. Anesthesiology 1981; 55: 292-6.
176. Eckenhoff R, Zheng W, Kelz M. From anesthetic mechanisms research to drug discovery. Clin Pharmacol Ther 2008; 84(1): 144-8.
177. Kanduc D. Correlating low-similarity peptide sequences and allergenic epitopes. Curr Pharm Des 2008; 14(3): 289-95.
178. Muehlbauer PA, Spellman RA, Gunther WC, Sanok KE, Wiersch CJ, O'Lone SD, et al. Improving dose selection and identification of aneugens in the in vitro chromosome aberration test by integration of flow cytometry-based methods. Environ Mol Mutagen 2008; 49(4): 318-27.